Forest Laboratories has announced it will discontinue sale of NAMENDA tablets on August 15.

The company will continue to sell the oral solution of NAMENDA and once-daily extended release capsules.

Forest Laboratories stressed the discontinuation was not due to any safety problem but rather a decision to focus on the once-daily NAMENDA XR capsules. This is an extended-release formulation of the drug for treatment of moderate to severe Alzheimer’s disease.